Capital International Investors Portfolio holdings
Capital International, established in 1968 as a division of the Los Angeles-based Capital Group, is a global investment management firm focused on delivering equity investment solutions for institutional and individual clients worldwide. Operating as part of one of the oldest and largest asset managers, founded in 1931, it leverages Capital Group’s signature research-driven, long-term investment philosophy, managing billions in assets through a multi-manager system that diversifies risk and enhances performance. Headquartered in Los Angeles with a presence across North America, Europe, and Asia, Capital International specializes in international and global equity strategies, often through mutual funds like those in the American Funds family. Known for its rigorous fundamental analysis and commitment to client outcomes, it plays a key role in Capital Group’s mission to provide consistent, superior returns in global markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$1.93B |
| 2 |
Bristol-Myers Squibb
BMY
|
+$1.16B |
| 3 |
Albemarle
ALB
|
+$741M |
| 4 |
FRC
First Republic Bank
FRC
|
+$599M |
| 5 |
VICI Properties
VICI
|
+$593M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$1.16B |
| 2 |
Netflix
NFLX
|
+$1.04B |
| 3 |
Meta Platforms (Facebook)
META
|
+$872M |
| 4 |
EOG Resources
EOG
|
+$800M |
| 5 |
Intercontinental Exchange
ICE
|
+$700M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.46% |
| 2 | Healthcare | 16.89% |
| 3 | Financials | 14.17% |
| 4 | Communication Services | 10.18% |
| 5 | Industrials | 9.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Lockheed Martin
LMT
$138B
| $243M | 0.07% |
566,322
-208,256
| -27% | -$91.4M |
|
227
VeriSign
VRSN
$25.6B
| $243M | 0.07% |
1,454,670
-2,420,846
| -62% | -$444M |
|
228
PepsiCo
PEP
$191B
| $241M | 0.07% |
1,445,046
-184
| -0% | -$31K |
|
229
Alnylam Pharmaceuticals
ALNY
$30.3B
| $238M | 0.06% |
+1,634,237
| New | +$232M |
|
230
Shopify
SHOP
$198B
| $235M | 0.06% |
7,514,185
-1,351,265
| -15% | -$57.7M |
|
231
Unilever
UL
$135B
| $232M | 0.06% |
4,495,689
+13,426
| +0.3% | +$684K |
|
232
Hilton Grand Vacations
HGV
$3.47B
| $231M | 0.06% |
6,476,349
-556,935
| -8% | -$24.8M |
|
233
Sea Limited
SE
$75.5B
| $230M | 0.06% |
3,434,701
+16,599
| +0.5% | +$1.41M |
|
234
Strategy Inc
MSTR
$37.4B
| $227M | 0.06% |
13,839,490
+14,860
| +0.1% | +$430K |
|
235
Guardant Health
GH
$21.6B
| $225M | 0.06% |
5,577,865
+496,241
| +10% | +$24.6M |
|
236
PACCAR
PCAR
$68.4B
| $224M | 0.06% |
4,085,192
-6,073
| -0.1% | -$342K |
|
|
BHVN
237
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $222M | 0.06% |
1,525,365
-1,157,551
| -43% | -$148M |
|
238
Etsy
ETSY
$7.33B
| $221M | 0.06% |
3,016,171
+878,285
| +41% | +$80.2M |
|
|
XYZ
239
Block Inc
XYZ
$48.7B
| $218M | 0.06% |
3,555,040
-385,005
| -10% | -$35.2M |
|
240
Burlington
BURL
$22.2B
| $211M | 0.06% |
1,547,870
+15,682
| +1% | +$2.84M |
|
|
B
241
Barrick Mining
B
$67.2B
| $211M | 0.06% |
11,913,985
-1,065,293
| -8% | -$23.1M |
|
242
Royalty Pharma
RPRX
$26.2B
| $210M | 0.06% |
4,994,607
+1,017
| +0% | +$41.7K |
|
243
Simpson Manufacturing
SSD
$8.02B
| $204M | 0.06% |
2,025,711
-57,803
| -3% | -$6M |
|
244
Ultragenyx Pharmaceutical
RARE
$2.63B
| $204M | 0.06% |
3,412,406
+67,380
| +2% | +$4.15M |
|
|
NARI
245
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $198M | 0.05% |
2,919,064
+81,019
| +3% | +$5.82M |
|
246
Lam Research
LRCX
$430B
| $194M | 0.05% |
4,544,500
+17,000
| +0.4% | +$809K |
|
247
Vail Resorts
MTN
$5.24B
| $192M | 0.05% |
880,820
+199
| +0% | +$48.7K |
|
|
AL
248
DELISTED
Air Lease Corp
AL
| $189M | 0.05% |
5,668,399
-1,169,261
| -17% | -$44.3M |
|
249
iShares MSCI EAFE ETF
EFA
$80.4B
| $185M | 0.05% |
2,947,778
+1,721,784
| +140% | +$117M |
|
250
Rio Tinto
RIO
$161B
| $185M | 0.05% |
3,016,603
-127,865
| -4% | -$9.16M |
|
Similar funds
Capital International Investors's Q2 2022 Portfolio in Review
As of Q2 2022, Capital International Investors held 470 positions worth $368B, down 16% from $439B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Capital International Investors's Q2 2022 filing shows 16 new, 197 increased, 171 reduced and 33 closed positions. Its largest new stake was Albemarle: 3,322,014 shares worth $694M. The largest sale was Eli Lilly, an estimated $1.16B.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
- Capital International Investors's largest Q2 2022 buy was Albemarle: 3,322,014 shares worth $694M.
- Capital International Investors added most to AbbVie in Q2 2022, an estimated $1.93B increase.
- Capital International Investors's biggest Q2 2022 reduction was Eli Lilly, cutting an estimated $1.16B.
- Capital International Investors fully exited Marriott International in Q2 2022, selling an estimated $359M.
- Capital International Investors's ten largest holdings make up 27% of its $368B portfolio in Q2 2022.
- Capital International Investors opened 16 new positions and closed 33 in Q2 2022.
- Capital International Investors's portfolio value fell 16% quarter-over-quarter to $368B.
Based on Capital International Investors's 13F filing for Q2 2022, filed 15 Aug 2022.